Biomea Fusion Reports Sustained Diabetes Efficacy with Icovamenib and Advances Obesity Pipeline with BMF-650
核心洞察
Biomea Fusion's icovamenib demonstrated durable 1.5% HbA1c reduction at 52 weeks in severe insulin-deficient diabetes patients, nine months after completing just 12 weeks of dosing.
The company initiated Phase I dosing of BMF-650, its next-generation oral GLP-1 receptor agonist for obesity, following promising preclinical data in nonhuman primates.
Preclinical combination studies showed icovamenib plus semaglutide achieved superior glycemic control and body weight reduction while preserving lean mass compared to semaglutide alone.
Biomea Fusion reported sustained efficacy from its oral menin (搜索) inhibitor icovamenib in diabetes patients, with durable HbA1c reductions persisting nine months after treatment completion, while advancing its obesity pipeline with first-in-human dosing of BMF-650, a next-generation oral GLP-1 receptor agonist.
The clinical-stage diabetes and obesity company announced positive 52-week follow-up results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes. In patients with severe insulin-deficient diabetes receiving one or more antihyperglycemic agents at baseline, icovamenib achieved a sustained 1.5% mean reduction in HbA1c at Week 52, following only 12 weeks of dosing (Arm B, p = 0.01).
"Icovamenib demonstrated continued reduction in HbA1c, nine months-post dosing in both of our identified target populations while maintaining a safety profile similar to placebo," said Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion. "These findings support our thesis that menin (搜索) inhibition can potentially address the underlying cause of diabetes."
Durable Efficacy in Multiple Patient Populations
The 52-week analysis also demonstrated clinically meaningful benefit in study participants who were receiving GLP-1-based therapy but had not achieved glycemic targets at study entry. In this subgroup of 11 patients across all arms, 8 or 12 weeks of icovamenib resulted in a 1.3% reduction in HbA1c.
Icovamenib was generally well tolerated across all dosing arms, with no treatment-related serious adverse events or discontinuations due to adverse events observed during the 52-week observation period.
Combination Therapy Potential
At the 61st European Association for the Study of Diabetes (EASD) Annual Meeting, Biomea presented preclinical data demonstrating enhanced activity of icovamenib in combination with semaglutide in a type 2 diabetes animal model. The combination therapy achieved superior glycemic control, improved beta-cell function, and greater body-weight reduction while preserving lean mass, compared to semaglutide alone.
Obesity Pipeline Advancement
Biomea's next-generation oral small molecule GLP-1 receptor agonist BMF-650 has entered Phase I clinical testing for obesity. The Investigational New Drug application was accepted, and the first patient has been dosed in a Phase I study that will assess the 28-day weight loss potential of BMF-650 in obese, otherwise healthy volunteers through several single ascending and multiple ascending dose cohorts.
The company presented new preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating BMF-650, which led to marked reductions in food intake and progressive body weight reductions. These data compared favorably to published preclinical data of another leading oral GLP-1 receptor agonist candidate in development.
Clinical Development Timeline
Icovamenib is advancing rapidly into two Phase II studies. The Food Effect Study (COVALENT-121) is ongoing to optimize dosing criteria and is expected to be completed by December 2025. Initiation of the Phase IIb trial (COVALENT-211) in severe insulin-deficient type 2 diabetes patients is expected in the fourth quarter of 2025, with first patient enrollment expected in the first quarter of 2026.
A second Phase II trial (COVALENT-212) in type 2 diabetes patients currently not achieving glycemic targets on GLP-1-based therapy is also expected to initiate in the fourth quarter of 2025, with first patient enrollment in the first quarter of 2026.
For BMF-650, the ongoing Phase I trial (GLP-131) in obese, otherwise healthy volunteers is anticipated to deliver 28-day weight reduction data in the first half of 2026.
Financial Position and Operations
Biomea completed an underwritten public offering in October 2025, raising approximately $25.0 million in gross proceeds. Combined with earlier fundraising, the company raised approximately $68 million in gross proceeds through two public offerings, extending its projected cash runway into the first quarter of 2027.
The company continued operational streamlining during the third quarter, reducing its workforce to approximately 40 employees and achieving a year-over-year decrease of more than 50% in operating expenses. As of September 30, 2025, Biomea had cash, cash equivalents and restricted cash of $47.0 million.
Biomea Fusion targets metabolic disorders, which the company notes affect nearly half of Americans and one-fifth of the world's population. The company's mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions.